This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Lung Cancer  • Tobacco  • Pulmonary Diseases  • Pulmonary Diseases, Other  • Women's Health  • Women's Health, Other  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic  Social Bookmarking   What's this?

Tracy Hampton, PhD

JAMA. 2009;302(6):615-616.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

A secondary analysis from the Women's Health Initiative has found that past use of hormone therapy with estrogen plus progestin increases the risk of dying from non–small cell lung cancer for women who develop the disease.

The findings, presented at the 45th Annual Meeting of the American Society of Clinical Oncology in Orlando, Fla, add to growing concerns about the safety of hormone therapy in some women. "These data, together with recent results indicating higher breast cancer risk, suggest cancer impact should influence risk-to-benefit consideration for combined hormone therapy use," the authors noted.

The Women's Health Initiative is a randomized, placebo-controlled clinical trial evaluating the health effects of conjugated equine estrogen plus medroxyprogesterone acetate in 16 608 postmenopausal women. Previous research has suggested that hormones may play a role in the progression of non–small cell lung cancer because women tend to have higher survival rates than men and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?